Eli Lilly’s LLY0.57%increase; green up pointing triangle late-stage study of the efficacy and safety of a treatment for type 2 diabetes has produced positive results. Achieve-4, the longest phase 3 ...

Eli Lilly's acquisition spree shows no sign of stalling, although the Big Pharma is keeping the terms of its latest buy pretty vague. This time, Lilly has returned to antibody-drug conjugates (ADCs), ...

HOUSTON--(BUSINESS WIRE)--CrossBridge Bio, Inc., a pre-clinical biotechnology company pioneering the development of next-generation dual-payload antibody-drug conjugates (ADCs) today announced a ...

Eli Lilly’s LLY0.66%increase; green up pointing triangle Foundayo weight-loss pill is now available in the U.S. following the Food and Drug Administration’s approval earlier this month, the company ...

Eli Lilly opposes the White House's push to codify 'most favored nation' drug pricing, Lilly CEO Dave Ricks said in an interview with CNBC. Lilly is one of more than a dozen pharmaceutical companies ...

Eli Lilly & Co.’s Zepbound is helping to solve one of the most intractable health challenges of our time: obesity. Now, the drugmaker is taking on another significant public health predicament: sleep ...

Eli Lilly plans to acquire Centessa Pharmaceuticals, which has been conducting a midstage clinical trial of its lead drug. By Rebecca Robbins Eli Lilly reached a deal on Tuesday to buy Centessa ...

With shares up 20% over the past 12 months, Eli Lilly appears to have come out on top in the battle to dominate the weight-loss drug market, with rival Novo Nordisk sinking 52% over the same period.

Eli Lilly (LLY) shares slipped in the premarket on Tuesday after HSBC downgraded the weight loss drugmaker to Reduce from Hold, issuing the pharma giant’s only sell-equivalent rating on Wall Street, ...

Roseanne Barr is opening up about the dynamics behind the scenes of her hit sitcom "Roseanne." During a recent episode of "The Roseanne Barr Podcast," the 73-year-old comedian spoke with Michael ...

Eli Lilly is a market darling at the moment because of its industry-leading GLP-1 drugs. The stock looks priced for perfection despite a well-known drug cycle. That's good news, but investors are well ...

Forget the drug discovery hype. Here’s how the world’s largest pharma company is seeing a payoff from AI right now. There’s been huge hype around AI’s potential for drug discovery. But at Eli Lilly, ...